U.S. Stem Cell, Inc. (USRM)

OTCMKTS: USRM · Delayed Price · USD
0.0000
-0.0001 (-99.00%)
Jan 9, 2024, 12:55 PM EDT - Market closed

Company Description

U.S. Stem Cell, Inc., a biotechnology company, engages in the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States.

The company's lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia.

Its pipeline products include MyoCell SDF-1, an autologous muscle-derived cellular therapy for enhancing cardiac function in chronic heart failure patients.

The company is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure.

In addition, it provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well as operates a cell therapy clinic to provide cellular treatments for patients afflicted with neurological, autoimmune, orthopedic, and degenerative diseases.

The company also offers various courses for physicians and other health care professionals. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015.

U.S. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida.

U.S. Stem Cell, Inc.
Country United States
Founded 1999
IPO Date Feb 15, 2008
Industry Biotechnology
Sector Healthcare
CEO Michael Tomas

Contact Details

Address:
1560 Sawgrass Corporate Pkwy, 4th Floor
Sunrise, Florida 33323
United States
Phone 954-835-1500
Website us-stemcell.com

Stock Details

Ticker Symbol USRM
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001388319
CUSIP Number 90350U100
ISIN Number US90350U1007
Employer ID 65-0945967
SIC Code 8731

Key Executives

Name Position
Michael Tomas Chief Executive Officer, President, Chief Financial Officer and Director
Dr. Colleen Robb Senior Compliance Officer
Phil Posa Senior Vice President of U.S. and International Sales
Evelyn Flores Corporate Controller
Dr. Sergio Pinski Medical Director and Member of Scientific Advisory Board

Latest SEC Filings

Date Type Title
May 15, 2023 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Apr 14, 2023 10-K Annual Report
Mar 31, 2023 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Nov 9, 2022 10-Q Quarterly Report
Aug 22, 2022 10-Q Quarterly Report
Aug 15, 2022 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Jul 8, 2022 10-K/A [Amend] Annual report
May 23, 2022 10-Q Quarterly Report
May 16, 2022 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Mar 31, 2022 10-K Annual Report